Last updated on August 2018

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors


Brief description of study

This is an open-label, multicenter, single-arm, two-stage, Phase Ib study designed to assess the safety, tolerability, and pharmacokinetics of oral cobimetinib with intravenous (IV) atezolizumab and bevacizumab in participants with metastatic colorectal cancer (mCRC) who have received and progressed on at least one prior line of therapy that contained a fluoropyrimidine and oxaliplatin or irinotecan. There are two stages in this study: Stage 1 (safety run-in phase) and Stage 2 (dose expansion phase with two cohorts, an expansion cohort and a biopsy cohort).

Clinical Study Identifier: NCT02876224

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: CO39083 ...

University Of Colorado
Aurora, CO United States

Reference Study ID Number: CO39083 ...

Dana-Farber Cancer Institute
Boston, MA United States

Reference Study ID Number: CO39083 ...

Memorial Sloan-Kettering Cancer Center
New York, NY United States

Reference Study ID Number: CO39083 ...

Duke Clinical Research Institute
Durham, NC United States

Reference Study ID Number: CO39083 ...

Sarah Cannon Research Inst.
Nashville, TN United States

Reference Study ID Number: CO39083 ...

The University of Texas MD Anderson Cancer Center
Houston, TX United States

Reference Study ID Number: CO39083 ...

Hospital Universitario Vall d'Hebron
Barcelona, Spain

Reference Study ID Number: CO39083 ...

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
Madrid, Spain

Reference Study ID Number: CO39083 ...

HCA Healthcare
London, United Kingdom